An interventional study of Ketogenic Diet and Ketone/Glucose Monitoring in Polycystic Kidney Disease, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Ohio State University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Polycystic Kidney Diseases with a site in United States — 9 open to participants now, 9 under way, 1 of them phase 3. Polycystic Kidney Diseases · United States.
Among the 32 studies in Polycystic Kidney Diseases with a site in United States, this one is the 13th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 with no phase, and was the 30th registered.
59 studies on the registry are indexed under Polycystic Kidney Diseases; 12 are open to participants now.
Browse Polycystic Kidney Diseases studies →9 of the 32 studies in Polycystic Kidney Diseases with a site in United States are open now. Recruiting first, the newest first:
Richard Fatica · Sites in United States
Ages 18+
Fetal Care Center, PLLC · Sites in United States
Women only
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States, Belgium, Germany and 3 more countries
Ages 28 days–18 yrs
PKD Foundation · Sites in United States
University of Kansas Medical Center · Sites in United States
Ages 4–35 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Polycystic Kidney Diseases studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 4
First in 2002; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 42 across 36 interventional studies indexed under Polycystic Kidney Diseases.
Median enrollment 25 across the 21 interventional studies, 300 across the 10 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 32 have an industry lead sponsor. The 10 most frequent:
Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
Ohio State University has 1 study filed under Polycystic Kidney Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Polycystic Kidney Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06325644Ohio State UniversityWell-Formulated Ketogenic Diet Polycystic Kidney Disease | 2026-12-01 |
| NCT07454174Richard FaticaMetabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Polycystic Kidney Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective study to determine ketogenic diet effect on htTKV, GFR, microalbuminuria. This is a single-center study of 20 patients with ADPKD and deemed high risk for progression to ESRD. This determined by combination of features of ADPKD and htTKV as assessed by prior computed tomography (CT) or MRI. Patients will be recruited from the Polycystic Kidney Disease (PKD) Clinic at Ohio State University Wexner Medical Center. Enrolled patients will have MRI for htTKV, urinary studies, blood tests at baseline, 6 months, and 52 weeks. Blood for GFR will be assessed three times over the course of the study including baseline, 6 months, and 1 year. Participants will follow ketogenic diet for 52 weeks. Investigatory diet team will manage the ketogenic diet.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The KD will follow general principles the investigators have described with the aim to achieve blood ketones \>0.5 mM, which will require most participants to consume \<50 g/day carbohydrate and \~1.5 g/kg reference weight protein. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods.
Other: Ketogenic Diet · Biological: Ketone/Glucose Monitoring · Biological: CGM/CKM · Biological: Blood Draw · Other: Body Composition · Other: Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .
The diet intervention will start after all baseline testing is complete
KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
Blood samples will be collected according to the schedule in Figure 1
DEXA Scanning will be done pre-, mid-, and post- intervention.
Changes in glomerular filtration rate will be assessed via magnetic resonance imagining conducted by trained professionals. MRI imaging analyses will determine cardiac function. Trained imaging professionals will analyze the images to determine overall change (mg/mmol).
Finger Stick Beta-Hydroxybutyrate
changes in fasting ketone levels.
Time frame: Up to ~ 52 Weeks
Finger Stick Glucose
changes in fasting glucose levels.
Time frame: Up to ~ 52 Weeks
Blood Pressure
Changes in both Systolic and Diastolic blood pressure will be measured at each lab visit (eg. Baseline, Week 6, and Week 12). Recording: The systolic and diastolic pressures are recorded in millimeters of mercury (mmHg). For example, a reading of "120/80 mmHg" indicates a systolic pressure of 120 mmHg and a diastolic pressure of 80 mmHg.
Time frame: Time Frame: Up to ~ 12 Weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.